202 related articles for article (PubMed ID: 1807823)
1. Treatment of polymyalgia rheumatica/giant cell arteritis.
Kyle V
Baillieres Clin Rheumatol; 1991 Dec; 5(3):485-91. PubMed ID: 1807823
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
Kyle V; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
[TBL] [Abstract][Full Text] [Related]
3. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
[TBL] [Abstract][Full Text] [Related]
4. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients.
Myklebust G; Gran JT
Scand J Rheumatol; 2001; 30(5):260-7. PubMed ID: 11727839
[TBL] [Abstract][Full Text] [Related]
5. Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.
Reilly PA; Maddison PJ
Clin Rheumatol; 1987 Jun; 6(2):270-2. PubMed ID: 3621844
[TBL] [Abstract][Full Text] [Related]
6. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.
Kyle V; Hazleman BL
Ann Rheum Dis; 1993 Dec; 52(12):847-50. PubMed ID: 8311533
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
De Silva M; Hazleman BL
Ann Rheum Dis; 1986 Feb; 45(2):136-8. PubMed ID: 3511861
[TBL] [Abstract][Full Text] [Related]
8. Polymyalgia rheumatica and corticosteroids: how much for how long?
Behn AR; Perera T; Myles AB
Ann Rheum Dis; 1983 Aug; 42(4):374-8. PubMed ID: 6882032
[TBL] [Abstract][Full Text] [Related]
9. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.
Kyle V; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):662-6. PubMed ID: 2782976
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
Diamantopoulos AP; Hetland H; Myklebust G
Biomed Res Int; 2013; 2013():120638. PubMed ID: 24106691
[TBL] [Abstract][Full Text] [Related]
11. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.
Schmidt J; Warrington KJ
Drugs Aging; 2011 Aug; 28(8):651-66. PubMed ID: 21812500
[TBL] [Abstract][Full Text] [Related]
12. Polymyalgia rheumatica and giant cell arteritis--An ophthalmic emergency.
Durkin SR; Athanasiov PA; Crompton JL
Aust Fam Physician; 2006 Nov; 35(11):889-91. PubMed ID: 17099810
[TBL] [Abstract][Full Text] [Related]
13. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
van der Veen MJ; Dinant HJ; van Booma-Frankfort C; van Albada-Kuipers GA; Bijlsma JW
Ann Rheum Dis; 1996 Apr; 55(4):218-23. PubMed ID: 8733437
[TBL] [Abstract][Full Text] [Related]
14. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
15. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.
Gonzalez-Gay MA; Garcia-Porrua C; Miranda-Filloy JA; Martin J
Drugs Aging; 2006; 23(8):627-49. PubMed ID: 16964987
[TBL] [Abstract][Full Text] [Related]
16. Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.
Pioro MH
Prim Care; 2018 Jun; 45(2):305-323. PubMed ID: 29759126
[TBL] [Abstract][Full Text] [Related]
17. Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives.
Ferraccioli GF; Di Poi E; Damato R
Clin Exp Rheumatol; 2000; 18(4 Suppl 20):S58-60. PubMed ID: 10948766
[TBL] [Abstract][Full Text] [Related]
18. Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice.
Lally L; Spiera R
Best Pract Res Clin Rheumatol; 2018 Dec; 32(6):803-812. PubMed ID: 31427056
[TBL] [Abstract][Full Text] [Related]
19. Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.
Pountain GD; Keogan MT; Brown DL; Hazleman BL
Ann Rheum Dis; 1993 Oct; 52(10):730-3. PubMed ID: 8257209
[TBL] [Abstract][Full Text] [Related]
20. Alpha 1-antichymotrypsin, C-reactive protein and erythrocyte sedimentation rate in polymyalgia rheumatica and giant cell arteritis.
Pountain GD; Calvin J; Hazleman BL
Br J Rheumatol; 1994 Jun; 33(6):550-4. PubMed ID: 8205403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
